148 related articles for article (PubMed ID: 19132193)
21. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
[TBL] [Abstract][Full Text] [Related]
22. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
Massicotte P; Adams M; Marzinotto V; Brooker LA; Andrew M
J Pediatr; 1996 Mar; 128(3):313-8. PubMed ID: 8774496
[TBL] [Abstract][Full Text] [Related]
23. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
[TBL] [Abstract][Full Text] [Related]
24. IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
Diab YA; Ramakrishnan K; Ferrell B; Chounoune R; Alfares FA; Endicott KM; Rooney S; Corcoran J; Zurakowski D; Berger JT; Shankar V; Nath DS
Pediatr Crit Care Med; 2017 May; 18(5):e207-e214. PubMed ID: 28296662
[TBL] [Abstract][Full Text] [Related]
25. The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children.
Estepp JH; Smeltzer M; Reiss UM
Pediatr Blood Cancer; 2012 Jul; 59(1):105-9. PubMed ID: 22106013
[TBL] [Abstract][Full Text] [Related]
26. IV enoxaparin in pediatric and cardiac ICU patients.
Cies JJ; Santos L; Chopra A
Pediatr Crit Care Med; 2014 Feb; 15(2):e95-103. PubMed ID: 24335994
[TBL] [Abstract][Full Text] [Related]
27. An Evaluation of the Appropriateness of Initial Enoxaparin Dosing Among Pediatric Patients.
Altuwayjiri A; AlDarwish A; Alshuraim R
Cureus; 2023 Nov; 15(11):e48830. PubMed ID: 38106767
[TBL] [Abstract][Full Text] [Related]
28. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children.
Greene LA; Law C; Jung M; Walton S; Ignjatovic V; Monagle P; Raffini LJ
J Thromb Haemost; 2014 Sep; 12(9):1554-7. PubMed ID: 24943261
[TBL] [Abstract][Full Text] [Related]
29. Experience with intravenous enoxaparin in critically ill infants and children.
Crary SE; Van Orden H; Journeycake JM
Pediatr Crit Care Med; 2008 Nov; 9(6):647-9. PubMed ID: 18838932
[TBL] [Abstract][Full Text] [Related]
30. Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism.
Fan JL; Roberts LE; Scheurer ME; Yee DL; Shah MD; Lee-Kim YJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28521068
[TBL] [Abstract][Full Text] [Related]
31. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Lee YR; Vega JA; Duong HN; Ballew A
Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
[TBL] [Abstract][Full Text] [Related]
32. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy.
Friedrich E; Hameed AB
J Perinatol; 2010 Apr; 30(4):253-7. PubMed ID: 19829297
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.
van Oosterom N; Winckel K; Barras M
J Thromb Thrombolysis; 2019 Oct; 48(3):387-393. PubMed ID: 30945098
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis.
Musgrave KM; Webber K; Murphy P; Avery P; Biss TT
J Thromb Haemost; 2017 Dec; 15(12):2361-2366. PubMed ID: 28976613
[TBL] [Abstract][Full Text] [Related]
35. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.
Welsh RC; Gordon P; Westerhout CM; Buller CE; O'Neill B; Armstrong PW
Catheter Cardiovasc Interv; 2007 Sep; 70(3):341-8. PubMed ID: 17295333
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Deal EN; Hollands JM; Riney JN; Skrupky LP; Smith JR; Reichley RM
J Thromb Thrombolysis; 2011 Aug; 32(2):188-94. PubMed ID: 21465129
[TBL] [Abstract][Full Text] [Related]
37. Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved.
Nunez JM; Becher RD; Rebo GJ; Farrah JP; Borgerding EM; Stirparo JJ; Lauer C; Kilgo P; Miller PR
Am Surg; 2015 Jun; 81(6):605-9. PubMed ID: 26031274
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
[TBL] [Abstract][Full Text] [Related]
39. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
40. Optimal dose of enoxaparin in critically ill trauma and surgical patients.
Rutherford EJ; Schooler WG; Sredzienski E; Abrams JE; Skeete DA
J Trauma; 2005 Jun; 58(6):1167-70. PubMed ID: 15995464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
